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   Albumin has a fundamental role in human body. Its main tasks in blood are to regulate osmotic blood 
pressure, maintaining the pH, and transporting metabolites and drugs throughout the vascular system.  
Pharmacological studies of the interaction of drugs on HSA are important due to structural and functional 
changes of this vital protein; thus, here in this research the effect of valproate as a common drug for epilepsy 
disorders is evaluated in the presence of hexadecyl pyridinium bromide (HPB) as a positive surfactant in 
normal and fever condition. Electrochemical method was used to investigate the binding number of HPB 
molecules to HSA in the absence and presence of valproate by evaluating the concentration of free HPB in 
37oC and 42oC temperatures. HSA affinity for valproate binding studied via ligand binding process for 
normal and fever temperatures. The findings indicate that, there is a significant difference in valproate 
binding to albumin at physiological and pathological temperatures. The consequences are the same in the 
presence of HPB; in other words, HSA binding tendency to HPB in the presence of valproate was totally 
altered because of HSA major conformational changes in fever condition. In conclusion, corrected dosage of 
valproate is needed for fever condition relative to normal temperature and the patients under prescription of 
different medications in fever condition should have different orders due to the interferences of drugs.   
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INTRODUCTION 
   Albumin as the most dominant protein in human 
serum[1, 2] possess specific role in transporting 
metabolites and drugs in the vascular system[3, 
4]. This protein is a single strand (MW = 67.5 kD) 
including 585 amino acid with abundance of 40 
mg ml−1 in the blood plasma[5]. It has a high 
affinity binding sites for several endogenous and 
exogenous compounds such as metals such as 
Cu2+ and Zn2+, fatty acids, amino acids and 
metabolites and many drug materials[6-8] that 
pharmacological researches implies on the 
interaction of HSA and many drugs [9], which 
will be transported to other parts of the body[10]. 
This vital protein has been applied as a model 
protein for protein folding and ligand binding 
researches in recent years. In fact, may factors can 
possibly affect the structure and function of 
human serum albumin such as pH, temperature, 
and binding of different ligands [11]. Valproate  
(VPA) is an effective drug, which is used  widely 
for  treatment of different kinds of diseases such 
as seizure kinds both in adults and in children 
with epilepsy syndromes, acute bipolar 
depression, chronic disease, migraine ,and as 
adjuvant chemotherapy [12-14]. Hexadecyl 
pyridinium bromide (HPB) is a cationic surfactant 
including a positive head group and a 
hydrophobic tail [6]. Due to vita role of albumin 
in human body, evaluating the protein 
conformation alteration is essential for 
understanding protein stability and its 
effectiveness in medicine transferring[15]. Here in 
this research the effect of valproate in the 
presence of HPB on the conformation changes of 
HSA has been studied. 
 
MATERIALS AND METHODS 
     Human serum albumin and reagents with 
analytical grade were purchased from Sigma and  




Merck respectively. Phosphate buffer (10 mM, pH 
= 7.0) was used throughout the study. 0.2 mg/ml 
of albumin was prepared and used. 
Three electrode cells including HPB, silver nitrate 
as reference and valproate were used for electro-
chemical evaluations, equipped with a Teflon 
stopper with holes to hold electrodes in 
appropriate configurations for minimizing the 
solution resistance in the electrochemical study in 
this experiment. The binding interaction of HSA-
HPB(Hexadecyl pyridinium bromide)  in the 
presence of valproate at 37 oC and 42 oC was 
studied using a Fluke potentiometer. 
Electrochemical impedance measurements were 
performed at open circuit potential with proper 
redox potential as bias potential. Electrochemical 
signals were calibrated to HPB and valproate 
concentrations that were used in order to 
determine the concentrations of free HPB and 
valproate. HSA concentration was 0.2 mg/ml. 
Calibration was performed by adding 10, 20, 40, 
80, 200, 700, and 1500 μl of HPB solution. 
Finally, the ratio for HPB binding to each mole of 
macromolecule was calculated[6].  UV 
absorbance of Albumin in 280 nm in phosphate 




   The binding isotherms of HSA-Valproate 
interaction in the 37oC and 42oC temperatures are 
shown in figure1. As depicted in figure 1, HSA  
affinity for Valproate binding in the both 
temperatures are different, so fever condition 
promotes more ligand binding.  
Since HSA has a dual behavior with valproate in 
the range of temperatures, the effect of valproate 
on physicochemical properties of HSA 
investigated. To confirm temperature effect on 
HSA, absorbance of Albumin in 280 nm for 
temperature range of 35oC - 50oC is represented 
in figure 2. 
HPB as a cationic surfactant is a proper probe for 
lyses of HSA structural aspects. In figure 3, HSA-
HPB binding isotherms in the 37oC and 42oC are 
shown in figure 3. 
 
 
Figure1. Binding number of valproate molecule to HSA 
molecule increases as the concentration of this drug is 
enhanced (left 42oC and right 37oC). 
 
 
Figure 2. Absorbance of HSA in 280 nm in the range of 
35oC-50oC temperatures.   
   
 
Figure3.  Evaluation of HPB binding affinity to HSA (left 








Valproate may HPB-HSA interaction; therefore, 
isotherms of HPB-HSA interaction in the 
presence of therapeutic dose of valproate are 
illustrated in figure 4. 
 
 
Figure4.  Comparative evaluation of HPB binding affinity to 
HSA (left 37oC and right 42oC) in the  presence of 
therapeutic dose of valproate. 
 
DISSCUSSION 
   Temperature has important effects on the b 
inding properties of biomacromolecules[16]. In 
the literature, it is reported that changing of 
temperature from 37oC to 42oC, effects on the 
structural features of HSA[4]; as it is depicted 
in the figure 1, there is a specific difference in 
valproate binding affinity to HSA in 37oC and 
42oC.  
In fact, due to conformational changes in fever 
condition, HSA affinity for valproate is 
increased at 42oC relative to 37oC. In a way 
that HSA saturation of valproate at 42oC is 
corresponded to lower concentration of 
valproate in comparison with 37oC.  In other 
words, it is reasonable that increasing 
temperature probably opens new binding sites 
for valproate.  
This finding expresses that starting of ligand 
binding and saturation of the binding sites in 
the 37oC requires more concentrations of 
ligand. HSA beside the other functional role is a 
main drug carrier in the blood, it can be 
assumed that binding of some drugs can alter its 
function and structure. It is reported that 
interaction of acetaminophen with HSA induces 
conformational change on the protein[17]. 
Sodium valproate is a common drug that is used 
for epilepsy disease[18].  It can be concluded 
that, in the fever condition the bounded 
valproate is increased relative to free valproate 
due to the increment in HSA affinity for 
valproate; hence, it should be consider that 
therapeutic dose for valproate for physiologic 
and pathologic conditions are different.  In 
figure 2, it is emphasis in the effect of 
temperature effect on HSA structural aspects.  It 
is a reasonable to consider that binding of 
valproate may effects on the HSA structural 
aspects. Figure 3 shows the binding isotherms 
of HSA-HPB interactions in the absence of 
valproate in the 37oC and 42oC temperatures. 
In which HPB binds to HSA in dissimilar 
manners in different temperatures. As it is 
shown in figure3, fever condition reduces HSA 
affinity for HPB.  
It is expected that, valproate changes HSA 
physicochemical properties. Consequently, 
HSA-HPB interaction was investigated in the 
presence of therapeutic dose of valproate.  
Since HPB is a cationic ligand and valproate is 
an anionic drug, it is possible that an 
electrostatic interaction occurs between them. 
For correction of this unfavorable effect, 
probable interaction of HPB-valproate was 
studied separately.   
The results indicate that, these interactions 
occur in the very low concentration of HPB; 
therefore, they cannot influence on the binding 
isotherms HSA-HPB in the presence of 
valproate. Correspond to the binding isotherms 
of HSA-HPB interaction in the presence of 
valproate (see figure4), it seems that valproate 
increases HSA affinity for HPB binding. On the 
whole, these findings refer two proper effects; 
the first is the effect of valproate on the HSA 
structure in the 42oC that leads to the 
decrement of exposed binding site for HPB on 
the surface of the protein due to the mild 
structural change of HSA, and the second is a 
different manner of effectiveness of valproate 
on the HSA in the 42oC comparing with the 
37oC, as temperature changes from 37oC to 
42oC alters the structure of protein [7].  
The binding process of HPB to HSA in 
physiological temperature occurs in the wide 
range of HPB concentration, but it takes place 
in narrow range for 42oC. 





   Temperature plays main role in the affinity of 
HSA-valproate binding process. HSA-valproate 
interaction alters binding properties of HSA that 
lead to the structural and functional alteration on 
the protein. This effect is a considerable process 
in the 42oC relative to 37 oC. The maximum 
value of human body temperature in the 
pathological condition (fever) is 42oC; 
consequently, it can be concluded that, the 
therapeutic dose of valproate should be corrected 
for this condition. Another significant finding in 
this research is, while the patients consume 
valproate with other medications, they should 
have a different dosage prescription for these 
medications due to probable interferences. 
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